These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

260 related articles for article (PubMed ID: 20203507)

  • 61. Tight junctions and IBS--the link between epithelial permeability, low-grade inflammation, and symptom generation?
    Piche T
    Neurogastroenterol Motil; 2014 Mar; 26(3):296-302. PubMed ID: 24548256
    [TBL] [Abstract][Full Text] [Related]  

  • 62. Role of tumor necrosis factor-alpha and interleukin-10 gene polymorphisms in irritable bowel syndrome.
    van der Veek PP; van den Berg M; de Kroon YE; Verspaget HW; Masclee AA
    Am J Gastroenterol; 2005 Nov; 100(11):2510-6. PubMed ID: 16279907
    [TBL] [Abstract][Full Text] [Related]  

  • 63. The mast cell stabiliser ketotifen decreases visceral hypersensitivity and improves intestinal symptoms in patients with irritable bowel syndrome.
    Klooker TK; Braak B; Koopman KE; Welting O; Wouters MM; van der Heide S; Schemann M; Bischoff SC; van den Wijngaard RM; Boeckxstaens GE
    Gut; 2010 Sep; 59(9):1213-21. PubMed ID: 20650926
    [TBL] [Abstract][Full Text] [Related]  

  • 64. Tegaserod for female patients suffering from IBS with mixed bowel habits or constipation: a randomized controlled trial.
    Chey WD; Paré P; Viegas A; Ligozio G; Shetzline MA
    Am J Gastroenterol; 2008 May; 103(5):1217-25. PubMed ID: 18477346
    [TBL] [Abstract][Full Text] [Related]  

  • 65. Bacterial concepts in irritable bowel syndrome.
    Lin HC; Pimentel M
    Rev Gastroenterol Disord; 2005; 5 Suppl 3():S3-9. PubMed ID: 17713456
    [TBL] [Abstract][Full Text] [Related]  

  • 66. Clinical studies on alleviating the symptoms of irritable bowel syndrome.
    Kajander K; Korpela R
    Asia Pac J Clin Nutr; 2006; 15(4):576-80. PubMed ID: 17077079
    [TBL] [Abstract][Full Text] [Related]  

  • 67. Acute tryptophan depletion alters gastrointestinal and anxiety symptoms in irritable bowel syndrome.
    Shufflebotham J; Hood S; Hendry J; Hince DA; Morris K; Nutt D; Probert C; Potokar J
    Am J Gastroenterol; 2006 Nov; 101(11):2582-7. PubMed ID: 17029611
    [TBL] [Abstract][Full Text] [Related]  

  • 68. Mast cells count and serum cytokine levels in patients with irritable bowel syndrome.
    Goral V; Kucukoner M; Buyukbayram H
    Hepatogastroenterology; 2010; 57(101):751-4. PubMed ID: 21033222
    [TBL] [Abstract][Full Text] [Related]  

  • 69. Protease activated receptor 4 status of mast cells in post infectious irritable bowel syndrome.
    Han W; Wang Z; Lu X; Guo C
    Neurogastroenterol Motil; 2012 Feb; 24(2):113-9, e82. PubMed ID: 22151913
    [TBL] [Abstract][Full Text] [Related]  

  • 70. [Alterations of intestinal epithelial barrier and flora in the irritable bowel syndrome].
    Piche T
    Gastroenterol Clin Biol; 2009 Feb; 33 Suppl 1():S40-7. PubMed ID: 19303538
    [TBL] [Abstract][Full Text] [Related]  

  • 71. A new soy germ fermented ingredient displays estrogenic and protease inhibitor activities able to prevent irritable bowel syndrome-like symptoms in stressed female rats.
    Moussa L; Bézirard V; Salvador-Cartier C; Bacquié V; Houdeau E; Théodorou V
    Clin Nutr; 2013 Feb; 32(1):51-8. PubMed ID: 22727545
    [TBL] [Abstract][Full Text] [Related]  

  • 72. An update on irritable bowel syndrome: from diagnosis to emerging therapies.
    Chang JY; Talley NJ
    Curr Opin Gastroenterol; 2011 Jan; 27(1):72-8. PubMed ID: 21099429
    [TBL] [Abstract][Full Text] [Related]  

  • 73. Therapies aimed at the gut microbiota and inflammation: antibiotics, prebiotics, probiotics, synbiotics, anti-inflammatory therapies.
    Quigley EM
    Gastroenterol Clin North Am; 2011 Mar; 40(1):207-22. PubMed ID: 21333908
    [TBL] [Abstract][Full Text] [Related]  

  • 74. The placebo response rate in irritable bowel syndrome and inflammatory bowel disease.
    Sands BE
    Dig Dis; 2009; 27 Suppl 1():68-75. PubMed ID: 20203499
    [TBL] [Abstract][Full Text] [Related]  

  • 75. Inflammation in irritable bowel syndrome: Myth or new treatment target?
    Sinagra E; Pompei G; Tomasello G; Cappello F; Morreale GC; Amvrosiadis G; Rossi F; Lo Monte AI; Rizzo AG; Raimondo D
    World J Gastroenterol; 2016 Feb; 22(7):2242-55. PubMed ID: 26900287
    [TBL] [Abstract][Full Text] [Related]  

  • 76. Randomised clinical trial: the analgesic properties of dietary supplementation with palmitoylethanolamide and polydatin in irritable bowel syndrome.
    Cremon C; Stanghellini V; Barbaro MR; Cogliandro RF; Bellacosa L; Santos J; Vicario M; Pigrau M; Alonso Cotoner C; Lobo B; Azpiroz F; Bruley des Varannes S; Neunlist M; DeFilippis D; Iuvone T; Petrosino S; Di Marzo V; Barbara G
    Aliment Pharmacol Ther; 2017 Apr; 45(7):909-922. PubMed ID: 28164346
    [TBL] [Abstract][Full Text] [Related]  

  • 77. [Post-infectious irritable bowel syndrome].
    Pallotti F; Fogacci E; Frisoni C; Serra M; Bellacosa L; Carini G; Cremon C; De Giorgio R; Stanghellini V; Corinaldesi R; Barbara G
    Clin Ter; 2011; 162(2):157-61. PubMed ID: 21533323
    [TBL] [Abstract][Full Text] [Related]  

  • 78. Irritable bowel syndrome: methods, mechanisms, and pathophysiology. The confluence of increased permeability, inflammation, and pain in irritable bowel syndrome.
    Camilleri M; Lasch K; Zhou W
    Am J Physiol Gastrointest Liver Physiol; 2012 Oct; 303(7):G775-85. PubMed ID: 22837345
    [TBL] [Abstract][Full Text] [Related]  

  • 79. Therapeutic potential of ketotifen in irritable bowel syndrome (IBS) may involve changes in mast cells at sites beyond the rectum.
    O'Sullivan M
    Gut; 2011 Mar; 60(3):423; author rpely 423. PubMed ID: 20921205
    [No Abstract]   [Full Text] [Related]  

  • 80. Randomised controlled trial of mesalazine in IBS.
    Barbara G; Cremon C; Annese V; Basilisco G; Bazzoli F; Bellini M; Benedetti A; Benini L; Bossa F; Buldrini P; Cicala M; Cuomo R; Germanà B; Molteni P; Neri M; Rodi M; Saggioro A; Scribano ML; Vecchi M; Zoli G; Corinaldesi R; Stanghellini V
    Gut; 2016 Jan; 65(1):82-90. PubMed ID: 25533646
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 13.